Edition:
United Kingdom

Rockwell Medical Inc (RMTI.OQ)

RMTI.OQ on NASDAQ Stock Exchange Global Market

3.01USD
2:46pm GMT
Change (% chg)

$0.00 (+0.00%)
Prev Close
$3.01
Open
$3.01
Day's High
$3.04
Day's Low
$3.00
Volume
2,298
Avg. Vol
47,224
52-wk High
$6.92
52-wk Low
$2.90

Summary

Name Age Since Current Position

Benjamin Wolin

43 2018 Chairman of the Board

Stuart Paul

59 2018 President, Chief Executive Officer, Director

Angus Smith

35 2018 Principal Financial Officer

Jim McCarthy

2018 Senior Vice President - Corporate and Business Development

David Kull

51 2018 Principal Accounting Officer

Ajay Gupta

60 2009 Chief Scientific Officer

Charlie Shiner

2018 Vice President of Marketing

Raymond Pratt

67 2012 Chief Medical Officer

Lisa Colleran

60 2018 Director

John Cooper

59 2018 Independent Director

David Domzalski

50 2017 Independent Director

Mark Ravich

65 2018 Independent Director

Robin Smith

53 2016 Independent Director

Michael Rice

Co-Founder, LifeSci Advisors, LLC

Biographies

Name Description

Benjamin Wolin

Mr. Benjamin Wolin is Chairman of the Board of the Rockwell Medical, Inc. He was Chief Executive Officer and Co-Founder of Everyday Health, Inc., ("Everyday Health") from January 2002 to December 2016. Mr. Wolin is currently Chairman of Diplomat Specialty Pharmacy (NYSE:DPLO), the nation's largest independent specialty pharmacy. Mr. Wolin also serves on the Board of Directors of a Dance Biopharm, a privately-held biotechnology company focused on the development of Dance 501, a proprietary 'soft-mist' inhaled insulin product to treat diabetes. Mr. Wolin also serves as an advisor and board member to a variety of other leading technology and healthcare organizations. He is a graduate of Bowdoin College. We believe that Mr. Wolin's experience as a chairman of the board of directors of a public company and as the principal executive officer and a director of a company that completed an initial public offering provides him with unique insights into the dynamics of a growing company and the financial, accounting, governance and operational issues specific to public companies qualify him for service as a director of our Company. Mr. Wolin's term as a director will expire at the 2019 Annual Meeting and upon the election and qualification of his successor. Approval of the Declassification Amendments at the Annual Meeting will not affect Mr. Wolin's current term.

Stuart Paul

Mr. Stuart M. Paul has been appointed as President, Chief Executive Officer, Director of the Company, effective September 4, 2018. He has over 25 years of experience in the health care industry. Most recently, Mr. Paul has served as Corporate Officer, Head Global Toxicology Business at Abbott Laboratories, from 2017 until present, where Mr. Paul led a $700 million global toxicology business and had responsibility for integration of acquisitions, research and development, manufacturing and commercial operations. From 2015 to 2017, Mr. Paul served as General Manager of the USA East Region of Quest Diagnostics Incorporated, where he headed a $1.4 billion regional division and was responsible for managing all laboratory testing, patient services, logistics, commercial operations and other relevant support functions. From 2013 to 2015, Mr. Paul served as President Latin America, Renal Group of Baxter International, where he headed Baxter’s $700 million dialysis business with over 1,500 employees in Latin America. Mr. Paul received his MBA from Northwestern University with a concentration in Hospital & Health Services Management and his BA in Chemistry from Duke University. There are no arrangements between Mr. Paul and any other person pursuant to which Mr. Paul was appointed to serve as our Chief Executive Officer, nor are there any material transactions in which the Company is a participant in which Mr. Paul has a material interest.

Angus Smith

Mr. Angus W. Smith is Principal Financial Officer of the Company. Mr. Smith will join Rockwell Medical from Pernix Therapeutics, a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drugs, where he currently serves as Senior Vice President, Chief Business Officer and Principal Financial Officer. Prior to this role, he served as Vice President, Business Development & Strategic Planning, and as Vice President, M&A and Corporate Finance. Prior to joining Pernix, Mr. Smith worked in healthcare investment banking, most recently serving as a Director in the Healthcare Investment Banking Group at Cantor Fitzgerald. During his nearly decade-long investment banking tenure, Mr. Smith focused on providing strategic and financial advice to specialty pharmaceutical and healthcare companies. He holds a B.A. in Mathematical Economics from Colgate University.

Jim McCarthy

Mr. Jim McCarthy is Senior Vice President - Corporate and Business Development of the Company. Mr. McCarthy is a seasoned business development executive with more than three decades of experience in the life sciences industry, including a twenty-five year career with Bristol-Myers Squibb, a publicly-traded global biopharmaceutical company. During that time, he gained significant domestic and international corporate business development experience, executing a broad range of transactions including licensing deals, strategic alliances and acquisitions. More recently, Mr. McCarthy has served in numerous roles assisting small and emerging life science companies with strategic and commercial planning, venture financing, commercial initiatives and deal support on a global basis. In addition, he has held leading roles in the Licensing Executive Society as Chair of the Life Sciences Sector and with the Licensing Executive Society International Life Sciences Leadership Committee. He holds an MBA from Indiana University and a B.S. in Physical Therapy from SUNY Upstate Medical Center, and is a recipient of the Certified Licensing Professional designation.

David Kull

Mr. David Kull is a Principal Accounting Officer of Rockwell Medical, Inc. He has served as the Company’s Controller since 2007. Mr. Kull is a certified public accountant. In connection with his appointment in this role, Mr. Kull will continue to serve as Controller of the Company and will continue to oversee the Company’s accounting department and the preparation of the Company’s financial statements.

Ajay Gupta

Dr. Ajay Gupta, M.D., is a Chief Scientific Officer of Rockwell Medical Inc. Before joining the Company, Dr. Gupta spent the prior seven years as an Associate Professor of Medicine at UCLA and Charles Drew University Schools of Medicine, Los Angeles, CA, where he had an active nephrology practice. Prior to that, Dr. Gupta served on the faculties of Henry Ford Hospital, Detroit, MI, University of Alabama, Birmingham, State University of New York, Syracuse and Washington University, St. Louis. Dr. Gupta also completed a clinical fellowship in Nephrology from Wayne State University, Detroit, Michigan and a research fellowship in Nephrology from Washington University, St. Louis, Missouri. Dr. Gupta, who is the Founder and Chairman of the Indian Society for Bone and Mineral Research, earned his MBBS degree and completed his residency in Internal Medicine from All India Institute of Medical Sciences, New Delhi. Dr. Gupta is the inventor of Triferic® (Ferric Pyrophosphate Citrate), our FDA-approved iron maintenance therapy drug for dialysis patients. He has filed a number of patents in the areas of drugs, medical devices and diagnostic tests.

Charlie Shiner

Mr. Charlie Shiner is Vice President of Marketing of the Company. Mr. Shiner joins Rockwell Medical from Otsuka Pharmaceuticals, Ltd., a global pharmaceuticals company focused on the development and marketing of products for the diagnosis and treatment of diseases related to the central nervous system, oncology, gastroenterology, ophthalmology and cardiovascular areas. He most recently served as the marketing franchise leader for Otsuka's renal portfolio, where he successfully launched Otsuka's new therapeutic Jynarque and managed other key renal therapeutics. Previously, he held the roles of Director and Senior Product Manager, Digital Marketing at Otsuka America Pharmaceuticals. In these roles, Mr. Shiner was responsible for the digital marketing of cardio-renal products across applicable professional and consumer channels. Earlier in his career, Mr. Shiner spent 11 years at Pfizer, Inc. where among other roles, he worked to identify and execute upon strategic opportunities for Pfizer's clinical treatments within hospital accounts acrossthe United States. Mr. Shiner holds a B.S. in Business Administration from the University of California, Riversideand an M.B.A from Northern Illinois University.

Raymond Pratt

Dr. Raymond Dennis Pratt M.D. is a Chief Medical Officer of Rockwell Medical Inc. Dr. Pratt joined the Company in April 2012 as its Chief Medical Officer. Prior to joining the Company, Dr. Pratt worked at Shire PLLC from 2003 to 2010 as Vice President Research and Development and as the scientific leader in its Emerging Business Unit and Renal Business Unit. Previous roles at Shire included Vice President Global Clinical Medicine and Global Clinical Affairs and head of US Clinical Development. Dr. Pratt served in a consulting role at Quintiles, a global biopharmaceutical services company, as a vice president of strategic drug development innovation from August 2011 until joining the Company, and as an industry consultant during 2011 after leaving Shire. Prior to working at Shire, he was Senior Director, Clinical Research and Development at Eisai Medical Research from 1994 to 2003, where he was head of Central Nervous System and Internal Medicine clinical development. Dr. Pratt is a graduate of the University of Illinois College of Medicine and completed his nephrology fellowship at the Walter Reed Army Medical Center where he practiced nephrology and served as the Assistant Chief of Nephrology Services and Director of Dialysis Services from 1983 to 1985. Dr. Pratt was the recipient of a physician scientist training grant at Johns Hopkins School of Medicine and the recipient of a James Shannon New Investigator award from the NIH. He served as an Assistant Professor in the John Hopkins Department of Medicine and Nephrology from 1989 to 1993.

Lisa Colleran

Ms. Lisa N. Colleran is a Director of Rockwell Medical, Inc. She was Global President of LifeCell Corporation from August 2008 to April 2013 and served as its Chief Executive Officer from January 2012 to April 2013. She joined LifeCell in December 2002 as Vice President of Marketing and Business Development and served as Senior Vice President of Commercial Operations from July 2004 to August 2008. Prior to LifeCell, Ms. Colleran spent 20 years at Baxter Healthcare's Renal Division in various commercial and general management roles. Early in her career, Ms. Colleran was a renal dialysis nurse at Cornell Medical Center. She currently serves on the Board of Directors of Establishment Labs, an innovative breast implant company and Ariste Medical a company developing a new class of drug eluting medical devices. Ms. Colleran recently served as a board member for Novadaq Technologies, Inc., helping to oversee its $700M sale to Stryker Corporation. Ms. Colleran received her Bachelor of Science from Molloy College and her Masters in Business Administration from Loyola University of Chicago. We believe that Ms. Colleran's more than 30 years of experience leading medical device companies, growing markets and creating shareholder value qualify her for service as a director of our Company. Ms. Colleran's term as a director will expire at the 2020 Annual Meeting and upon the election and qualification of her successor. Approval of the Declassification Amendments at the Annual Meeting cannot legally shorten Ms. Colleran's term; however, she has expressed her intention to voluntarily submit her resignation from the Board after the Annual Meeting with the understanding that the Board would then immediately re-appoint her to the Board for a term to expire at the 2019 Annual Meeting and upon the election and qualification of her successor.

John Cooper

Mr. John G. Cooper is an Independent Director of Rockwell Medical, Inc. Mr. Cooper serves as Director of the company. Mr. Cooper is currently Founder and Principal of JGC Advisors, providing corporate development and financial advisory services to the life sciences industry. From 2013 to 2016, Mr. Cooper served as President, Chief Executive Officer and member of the Board of Directors for Windtree Therapeutics Inc. (formerly Discovery Laboratories, Inc.), a publicly traded specialty pharmaceutical company. From 2001 to 2013 at Discovery Labs, Mr. Cooper served in the following roles: President and Chief Financial Officer (2010 – 2013), Executive Vice President and Chief Financial Officer (2002 – 2010) and Senior Vice President and Chief Financial Officer (2001 – 2002). Prior to Discovery Labs, Mr. Cooper served as Senior Vice President and Chief Financial Officer at Chrysalis International Corporation, a publicly traded drug development services company with operations in six countries, and its predecessor DNX Corporation, a public biotechnology company, where he managed its initial public offering and negotiated and integrated a number of strategic acquisitions. Previously, Mr. Cooper served in a senior financial management role at ENI Diagnostics, Inc., an international medical device and diagnostics company. Mr. Cooper earned a Certified Public Accountant credential in 1985 and a Bachelor of Science degree in Commerce from Rider University in 1980. Mr. Cooper brings to the Board extensive experience in the life sciences industry, including executive management of companies engaged in development of biotechnology products, drug development services and medical device development. He has significant public company accounting and financial expertise, as well as experience in capital raising and alliance transactions in the life sciences industry.

David Domzalski

Mr. David T. Domzalski is an Independent Director of Rockwell Medical, Inc. Mr. Domzalski currently serves as President of the U.S. subsidiary of Foamix Pharmaceuticals Inc., a position he has held since April 2014. Prior to his tenure at Foamix, Mr. Domzalski was Vice President of Sales & Marketing, at LEO Pharma, Inc. where he led the efforts to design and build-out the U.S. commercial operations, overseeing approximately 200 employees across multiple functional areas. He successfully managed the turnaround of Leo Pharma’s psoriasis franchise from a 2-year prescription decline to an annual growth of 26%. Mr. Domzalski was responsible for the strategic re-launch of Taclonex® Topical Suspension which resulted in Taclonex being reestablished as the number one brand in the category. Prior to LEO Pharma, Mr. Domzalski was the Senior Vice President and General Manager of the Women’s Health & Urology division of Azur Pharma, where he had full P&L responsibility for a start-up business unit. Before Azur, Mr. Domzalski spent 5 years from 2003 to 2008 as the Vice President of Sales & Marketing for Warner Chilcott, where he directed all commercial efforts for in-line brands focused on therapeutic areas of dermatology, women’s health and urology. His achievements at Warner Chilcott included the launch of four products within a twelve month period, including Taclonex for psoriasis and Doryx® Tablets for acne. Mr. Domzalski led the structural design, development and growth of the commercial team at Warner Chilcott from 150 to 500 employees. Earlier in his career, Mr. Domzalski, held senior sales and marketing positions at Sanofi-Synthelabo, Pharmacia, Dendrite International and Parke-Davis. He earned a Bachelor of Arts in Economics and Political Science from Muhlenberg College.

Mark Ravich

Mr. Mark H. Ravich, age 65, has been a director since June 2017. Mr. Ravich currently serves as president of Tri-Star Management, Inc., a commercial real estate management and syndication company that he co-founded in 1998. Mr. Ravich has also served as a director of Orchids Paper Products Company, a national supplier of high quality consumer tissue products, since February 2013, where he also serves as chairman of its governance committee and a member of its audit committee. Mr. Ravich has also served as a director of each of MR Instruments, Inc., an independent designer and manufacturer of advanced MRI Radiofrequency coils, since June 2004, and Dilon Technologies Inc., a designer and manufacturer of medical imaging solutions, since October 2010. Previously, from 1990 until its sale in 1998, Mr. Ravich served as the chief executive officer and a director of Universal International, Inc., a wholesale retail company, where he also led its IPO. From 1978 to 1990, Mr. Ravich was a developer of commercial real estate where he was involved with all aspects of development, finance, construction, marketing, leasing and management of various commercial, industrial, office and multi-family real estate projects. Mr. Ravich began his career in 1975 as an account officer at Citibank N.A., where he made real estate construction loans to national real estate developers. Mr. Ravich also currently serves as a board advisor to Scidera Inc., a provider of clinical laboratory testing services, and is the chief manager of various real estate entities. Mr. Ravich graduated Magna Cum Laude from the Wharton School of the University of Pennsylvania with a BSE and an MBA degree with a major in finance. We believe that Mr. Ravich's experience as a member of a board of directors of a public company and his experience as a senior leader of his own company qualify him for service as a director of our Company. Mr. Ravich's term as a director will expire at the 2020 Annual Meeting and upon the election and qualification of his successor.

Robin Smith

Dr. Robin L. Smith, M.D. is an Independent Director of Rockwell Medical, Inc. Dr. Smith has been a director since June 2016. Dr. Smith currently serves as the president and chairman of the board of The Stem for Life Foundation. From June 2006 to December 2014, Dr. Smith, served as Chief Executive Officer of Caladrius Biosciences, Inc. (formerly NeoStem, Inc.). She also served as Chairman of the Board of Caladrius Biosciences, Inc. during that tenure and until December 2015. During her tenure at Caladrius, she pioneered the company's innovative business model, combining proprietary cell therapy development with a successful contract development and manufacturing organization, while leading the company's successful capital raising and acquisition efforts. Dr. Smith's previous work experience includes serving as President and Chief Executive Officer of IP2M, a multi-platform media company specializing in healthcare, from 2000 to 2003. She also previously held the position of Executive Vice President and Chief Medical Officer for HealthHelp, Inc., a national radiology management company, from 1998 to 2000. Dr. Smith earned her M.D. from Yale University and her M.B.A. from the Wharton School of Business. She currently serves as chairman of the board of directors of MYnd Analytics, Inc. and serves on the board of directors of other privately owned biotech companies, hospitals and foundations. Dr. Smith previously served on the board of directors of Miragen Therapeutics, Inc. (formerly Signal Genetics, Inc.).

Michael Rice